United States 113th Congress Status: Died 1 I cosponsors

S 626 — Prize Fund for HIV/AIDS Act

Last action — Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Track this bill free

No card. One bill, free forever — alerts when it moves.

  1. ✓
    Introduced
  2. ✓
    In Committee
  3. Died in session

This bill died with 113th Congress. It reached “In Committee” and never advanced before the session ended, so it can no longer move — a new version would have to be reintroduced in the current session.

This bill is no longer active — its legislative session has ended, so there is no live prognosis. It would have to be reintroduced in the current session to move again.

Summary

Prize Fund for HIV/AIDS Act - Denies any person the exclusive right to manufacture, distribute, sell, or use in interstate commerce a qualifying treatment for HIV/AIDS, or to a manufacturing process for such a treatment, including the exclusive right to rely on health registration data or the 30-month stay-of-effectiveness period for Orange Book patents. Prescribes remuneration, in the form of prize payments from a Prize Fund for HIV/AIDS, in lieu of such market exclusivity. Exempts from this elimination of exclusive rights any dual use product that is a qualifying treatment for HIV/AIDS which also has a significant use for other diseases, but only with respect to its use for other diseases. Applies the elimination of exclusive rights with respect to a qualifying HIV/AIDS treatment even in a dual use product. Establishes the Prize Fund for HIV/AIDS. Requires the Secretary of Health and Human Services (HHS) to designate a Prize Fund Director to administer the Fund. Directs the Prize Fund Director to award prize payments for medical innovation relating to a qualifying treatment for HIV/AIDS, or a new manufacturing process for such a treatment, to: (1) the first person to receive market clearance with respect to the drug or biological product; (2) the holder of the patent with respect to a manufacturing process; or (3) persons or communities that as an open source contribution openly shared knowledge, data, materials, and technology on a royalty-free and nondiscriminatory basis. Allows the Prize Fund Director to authorize multiple nonprofit intermediaries to manage Fund payments to reward projects for: (1) interim research and development of new qualifying treatments for HIV/AIDS, or (2) open source dividend prizes. Establishes an annual fee for health insurers to fund this Act. Establishes the Donor Innovation Prize Fund to enable the Secretary to reward owners and developers of products that permit open competition for low-cost generic drugs for the treatment of HIV/AIDS in developing countries.

Bill Text

We don't have the full text on file for this bill yet.

Read S 626 on the official United States source →

Action History

  1. Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Sponsors

Sponsorship breakdown

Export CSV (upgrade) →

1 sponsors · 0 co-sponsors · 546 not signed on

Sponsors (1)

Co-sponsors (0)

None.

Not signed on (546)

546 members have not signed on to this bill.

Show all 546 →

"Not signed on" means a member has not sponsored or co-sponsored this bill — it does not imply opposition. Members flagged Voted No have a recorded No vote on this bill.

Whip count is in markup. Polling the chamber and every recorded vote this session. Only the first open is slow. It’s instant for you after this. Calling the roll · Tallying · Engrossing

Subjects

healthcare health-insurance technology
Cross-referencing the record. Reading this bill against every other bill in the corpus by meaning, not keywords. Only the first open is slow. It’s instant for you after this. Matching · Ranking · Engrossing

Frequently asked questions

What does S 626 do?
Prize Fund for HIV/AIDS Act - Denies any person the exclusive right to manufacture, distribute, sell, or use in interstate commerce a qualifying treatment for HIV/AIDS, or to a manufacturing process for such a treatment, including the exclusive right to rely on health registration data or the 30-month stay-of-effectiveness period for Orange Book patents. Prescribes remuneration, in the form of prize payments from a Prize Fund for HIV/AIDS, in lieu of such market exclusivity. Exempts from this elimination of exclusive rights any dual use product that is a qualifying treatment for HIV/AIDS which also has a significant use for other diseases, but only with respect to its use for other diseases. Applies the elimination of exclusive rights with respect to a qualifying HIV/AIDS treatment even in a dual use product. Establishes the Prize Fund for HIV/AIDS. Requires the Secretary of Health and Human Services (HHS) to designate a Prize Fund Director to administer the Fund. Directs the Prize Fund Director to award prize payments for medical innovation relating to a qualifying treatment for HIV/AIDS, or a new manufacturing process for such a treatment, to: (1) the first person to receive market clearance with respect to the drug or biological product; (2) the holder of the patent with respect to a manufacturing process; or (3) persons or communities that as an open source contribution openly shared knowledge, data, materials, and technology on a royalty-free and nondiscriminatory basis. Allows the Prize Fund Director to authorize multiple nonprofit intermediaries to manage Fund payments to reward projects for: (1) interim research and development of new qualifying treatments for HIV/AIDS, or (2) open source dividend prizes. Establishes an annual fee for health insurers to fund this Act. Establishes the Donor Innovation Prize Fund to enable the Secretary to reward owners and developers of products that permit open competition for low-cost generic drugs for the treatment of HIV/AIDS in developing countries.
Who sponsors S 626?
S 626 is sponsored by Bernard Sanders (I).
What is the current status of S 626?
This bill died with 113th Congress. It reached “In Committee” and never advanced before the session ended, so it can no longer move — a new version would have to be reintroduced in the current session.
Where can I track S 626?
Track S 626 free on One Click Politics — get push/email alerts when it moves.

Make your voice heard on S 626

Find the representatives who decide this bill and tell them where you stand — for yourself, or mobilize your whole list in one click with One Click Politics advocacy software.

Find my representatives → Run a campaign

Stay ahead of S 626

Last checked for changes about 11 hours ago · updated continuously

One Click Politics tracks every bill in Congress and all 50 states.

Track this bill →